Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extensionReportar como inadecuado




Sustained weight loss in patients treated with mifepristone for Cushing’s syndrome: a follow-up analysis of the SEISMIC study and long-term extension - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Endocrine Disorders

, 15:63

First Online: 27 October 2015Received: 15 April 2015Accepted: 16 October 2015

Abstract

BackgroundOverweight and obesity are common among patients with Cushing’s syndrome CS and may persist in some patients even after ostensibly curative surgery, contributing to cardiometabolic dysfunction and increased cardiovascular risk. Mifepristone, a selective glucocorticoid receptor antagonist, was effective in controlling hyperglycemia in a 24-week trial of adults N = 50 with endogenous CS and associated type 2 diabetes mellitus-impaired glucose tolerance or hypertension who had failed or were not candidates for surgery SEISMIC, Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome. This analysis examines long-term weight change among patients who received mifepristone in SEISMIC and enrolled in a long-term safety extension LTE study.

MethodsPatients completing the 24-week SEISMIC study and subsequent 6-week off-drug safety evaluation were invited to enroll in the LTE study. Mifepristone doses at the end of SEISMIC were the LTE starting doses. Body weight measures were reviewed at baseline and week 24 of SEISMIC and at LTE month 6, 12, 18, 24, and final visit last observation collected during the LTE study.

ResultsOf the 30 patients enrolled in the LTE, evaluable weight data were available for 29 20-29 female; mean age of 44.7 ± 11.2 years. These patients received mifepristone for a median of 29.2 months range 8.4–41.9. Mean ± SD weight from SEISMIC baseline to LTE final visit decreased by 10.3 ± 16.3 kg mean 105.4 ± 34.3 kg to 95.1 ± 32.9 kg, a 9.3 % decrease from baseline weight P = 0.0008. Of the 29 LTE patients, 18 62.1 % lost ≥5 % of body weight by the end of the initial 24-week treatment period; this ≥5 % weight loss persisted in 83.3 % 15-18 at LTE final visit. Ten patients 34.5 % lost ≥10 % of initial body weight by week 24 of SEISMIC, which persisted in 80 % at LTE final visit. No new safety signals were detected with long-term mifepristone use.

ConclusionClinically meaningful weight loss achieved during a 24-week study of mifepristone for CS persisted for two additional years in patients who remained on therapy. Long-term treatment with mifepristone appears to have a beneficial effect on weight in patients with endogenous CS.

Trial RegistrationNCT00569582 SEISMIC; NCT00936741 Long-Term Extension.

KeywordsCushing’s syndrome Korlym Long-term Mifepristone Obesity SEISMIC Weight loss AbbreviationsACTHAdrenocorticotropic hormone

BMIBody mass index

CDCushing’s disease

CSCushing’s syndrome

LTELong-term extension

SEISMICStudy of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome

Download fulltext PDF



Autor: Henry G. Fein - T. Brooks VaughanIII - Harvey Kushner - David Cram - Dat Nguyen

Fuente: https://link.springer.com/







Documentos relacionados